期刊
CURRENT OPINION IN HIV AND AIDS
卷 7, 期 5, 页码 456-462出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0b013e328356e933
关键词
CCR5; chemokine; co-receptor; HIV; maraviroc
资金
- Gilead Sciences
- Abbott
- University of New South Wales
- Pfizer-ViiV Healthcare [NCT01384682]
- Merck Sharp and Dohme
- Boehringer-Ingelheim
Purpose of review To summarise recently published clinical studies of chemokine receptor-5 (CCR5)-blockers, including the small-molecule blocker, maraviroc (MVC) and CCR5-monoclonal antibodies for HIV. MVC may have immunomodulating properties through CCR5-blockade. MVC appears well tolerated and penetrates the central nervous system. For these reasons, MVC is being investigated in immunodiscordance, prevention of IRIS and in HCV-HIV co-infection. Novel techniques allow tropism assignment via sequencing of proviral DNA; this testing platform is being utilised in MVC switch studies in those with HIV viraemia below the level of quantification. MVC is being utilised in regimen intensification studies for HIV associated neurocognitive disease. Recent findings MVC has no anti-inflammatory activity in rheumatoid arthritis. MVC appears well tolerated in hepatitis virus co-infected patients and MVC-intensification in HCV-HIV co-infection suggests a favourable impact on liver fibrosis. Early pilot data suggests MVC intensification may have functional benefit in the CNS. There is a growing body of data on tropism testing using proviral DNA; this technology is being utilised in MVC switch studies. CCR5-monoclonal antibodies administered subcutaneously are promising in Phase II development. Summary The place of MVC as an anti-HIV drug in the switch setting and as an immunomodulator is yet to be fully determined.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据